Subject(s)
Bone Marrow , Langerhans Cell Sarcoma , Leukemia, Lymphocytic, Chronic, B-Cell , Neoplasms, Second Primary , Aged , Bone Marrow/diagnostic imaging , Bone Marrow/metabolism , Bone Marrow/pathology , Humans , Langerhans Cell Sarcoma/diagnostic imaging , Langerhans Cell Sarcoma/drug therapy , Langerhans Cell Sarcoma/metabolism , Leukemia, Lymphocytic, Chronic, B-Cell/diagnostic imaging , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Neoplasms, Second Primary/diagnostic imaging , Neoplasms, Second Primary/drug therapy , Neoplasms, Second Primary/metabolism , Neoplasms, Second Primary/pathologySubject(s)
Antineoplastic Agents/therapeutic use , Drug Resistance, Neoplasm/drug effects , Imidazoles/therapeutic use , Langerhans Cell Sarcoma/drug therapy , Oximes/therapeutic use , Salvage Therapy/trends , Antineoplastic Agents/pharmacology , Humans , Imidazoles/pharmacology , Langerhans Cell Sarcoma/diagnostic imaging , Langerhans Cell Sarcoma/genetics , Male , Middle Aged , Oximes/pharmacology , Proto-Oncogene Proteins B-raf/genetics , Treatment OutcomeSubject(s)
Antineoplastic Agents/therapeutic use , Imidazoles/therapeutic use , Langerhans Cell Sarcoma/drug therapy , Molecular Targeted Therapy , Neoplasm Proteins/antagonists & inhibitors , Oximes/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Azetidines/administration & dosage , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Drug Resistance, Neoplasm , Drug Substitution , Humans , Indoles/administration & dosage , Langerhans Cell Sarcoma/diagnostic imaging , Langerhans Cell Sarcoma/genetics , Langerhans Cell Sarcoma/pathology , Lymph Nodes/diagnostic imaging , Lymph Nodes/pathology , MAP Kinase Kinase Kinases/antagonists & inhibitors , MAP Kinase Kinase Kinases/biosynthesis , MAP Kinase Kinase Kinases/genetics , Male , Middle Aged , Multimodal Imaging , Mutation, Missense , Neoplasm Proteins/genetics , Piperidines/administration & dosage , Point Mutation , Positron-Emission Tomography , Prednisone/administration & dosage , Proto-Oncogene Proteins/antagonists & inhibitors , Proto-Oncogene Proteins/biosynthesis , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins B-raf/genetics , Recurrence , Sulfonamides/administration & dosage , Tomography, X-Ray Computed , Vemurafenib , Vincristine/administration & dosageABSTRACT
A 53-year-old man, who was a heavy smoker, presented with recent severe cough. Radiography demonstrated a large pulmonary mass in the right upper lung. FDG PET/CT demonstrated heterogeneous high-grade activity in the pulmonary mass located in the right upper lung (standardized uptake value of 20), with central necrosis, bilateral upper mediastinal lymphadenopathy, right supraclavicular lymphadenopathy, direct left sternal manubrium invasion, and distal bilateral peripheral lung metastasis. Histology revealed significant malignant cytologic features and CD1a- and S-100-positive cells by immunohistochemistry staining, typical for Langerhans cell sarcoma.
Subject(s)
Fluorodeoxyglucose F18 , Langerhans Cell Sarcoma/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Multimodal Imaging , Positron-Emission Tomography , Tomography, X-Ray Computed , Humans , Langerhans Cell Sarcoma/pathology , Lung Neoplasms/pathology , Male , Middle Aged , Whole Body ImagingSubject(s)
Langerhans Cell Sarcoma/pathology , Lung Neoplasms/pathology , Mediastinal Neoplasms/pathology , Multiple Pulmonary Nodules/pathology , Biopsy , Diagnosis, Differential , Endosonography , Humans , Langerhans Cell Sarcoma/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Male , Mediastinal Neoplasms/diagnostic imaging , Middle Aged , Multiple Pulmonary Nodules/diagnostic imaging , Neoplasm Invasiveness , Positron-Emission Tomography , Tomography, X-Ray ComputedABSTRACT
We describe the rare case of a 53-year-old woman with systemic involvement of Langerhans cell sarcoma (LCS) who had undergone living-related liver transplantation. We chose the CHOP regimen as first-line chemotherapy, and clinical improvement of LCS was obtained. Intensive care was necessary due to the systemic involvement of LCS and severe infectious diseases. After the third cycle of CHOP therapy, however, disease progression was observed, and we administrated a modified ESHAP regimen (etoposide, carboplatin, cytarabine, methylprednisolone) as second-line therapy. A marked response was obtained after four cycles of this combination chemotherapy. Modified ESHAP may be a very effective combination chemotherapy regimen for LCS.